Vertical AI Content for “merck lipfendra cholesterol pill”
Google Trends · Automated AI Business Plan

Vertical AI Content for “merck lipfendra cholesterol pill”

An AI writing, imagery and SEO content workflow for a hot vertical, on subscription.

Source keyword merck lipfendra cholesterol pill volume 2,000 · growth +100% · persistence: Flash trend (1 observations over 1 day) · intent: Informational (6/10) · category Health · region US · collected 07/16/2026, 04:02 PM
Lipfendra AI Navigator
11.3%
Seed 5-yr ROI (realized)
2.1%
5-yr annualized return
21%
Win rate (profitable exit)
4.2 : 1
Profit/loss ratio

Anchored on Google Trends keyword "merck lipfendra cholesterol pill" · Auto-generated by deterministic model, not manual due diligence · Narrative prose was generated in Chinese; framework labels are localized.

Executive Summary

Executive Summary

全自动AI平台,提供Merck Lipfendra降胆固醇药物的权威信息、用药辅助与个性化健康建议。

智能解读新药,守护心血管健康

Lipfendra热度激增,用户亟需可信、易懂的AI健康信息服务。

Seed return at a glance (realized / cash basis): Cumulative ROI of Y1 -68.5%, Y2 -42.8%, Y3 -21.7%, Y4 -3.9%, Y5 11.3%; ~2.1% 5-yr annualized; win rate (profitable exit) ~21.5%; profit/loss ratio ~4.19:1; expected MOIC ~1.11×.
Source Hot Keyword

Source Hot Keyword

This plan anchors on a single top-ranked Google Trends keyword and derives from it the highest-ROI fully-online (web service) opportunity. The table below is the full provenance snapshot of that source keyword (stored with the plan and auditable).

Source keywordmerck lipfendra cholesterol pill
Collection rank
Search volume2,000
Growth rate+100%
Trend persistencepersistence: Flash trend (1 observations over 1 day)
Commercial intentintent: Informational (6/10)
CategoryHealth
RegionUS
Collected at07/16/2026, 04:02 PM
Source tabletrending_now
Opportunity Selection

Opportunity Selection & Ranking

This plan auto-brainstorms from recent Google Trends keywords and ranks them with a transparent ROI model, selecting the fully-online (web service) opportunity with the highest return on investment.

RankOpportunityROI scoreOne-line positioning
1Lipfendra AI Navigator 5.94 全自动AI平台,提供Merck Lipfendra降胆固醇药物的权威信息、用药辅助与个性化健康建议。

Supporting trend evidence (sample)

merck lipfendra cholesterol pill · vol 2,000 · +100%
Problem

Problem

新药Lipfendra信息分散,患者难以理解风险、适应症与用药指导。

Solution

Solution

AI驱动的Lipfendra信息解读与用药辅助平台,自动匹配个体健康状况。

权威药品信息AI摘要

个性化用药风险评估

智能问答与健康建议

自动推送最新研究进展

Market

Market Analysis

TAM: 美国高胆固醇患者约9400万(CDC, 2023)

SAM: 关注Lipfendra新药用户约188万(2%渗透率,推算自搜索量)

SOM: 首年目标用户2万(1%SAM)

依据CDC与Google Trends数据,估算保守。

Product

Product & Service

权威药品信息AI摘要

个性化用药风险评估

智能问答与健康建议

自动推送最新研究进展

Business Model

Business Model & Unit Economics

基础版 · $9/月 · AI问答与药品摘要

专业版 · $29/月 · 个性化用药评估与健康报告

AI交付成本<$0.5/用户/月,毛利率>95%

Financial metricYear 1Year 2Year 3
Active users3,69410,26120,522
Paying users96267534
Revenue (¥)¥215,654¥599,789¥1,199,578
Gross profit (¥)¥176,837¥491,827¥983,654
Opex (¥)¥608,397¥983,409¥1,413,632
EBITDA (¥)¥-431,560¥-491,582¥-429,978

Unit economics: LTV $768 · effective CAC $224 · LTV/CAC 3.42:1 (healthy ≥3:1, credible cap 6:1) · payback 10.53 months · avg lifetime 3 years.

Year-3 indicative exit EV ≈ ¥0 (at 4× SDE/EBITDA, online-asset M&A benchmark).

This table is computed by the deterministic benchmark model; if narrative prose mentions different financial figures, this table is authoritative (the prose is generation-time text, while the model has been recomputed with the latest version).

Seed Returns

Seed Return Analysis

Methodology: 实现口径(现金 cash-on-cash / “拿到钱”)。失败、以及存活但未发生流动性事件的“僵尸”均计 0 实现回报;仅成功退出(并购/二级转让/回购/分红回本)计入收益。

1. Seed-round ROI by year (realized)

Holding periodCumulative ROIAnnualized return
Year 1 -68.50% -68.50%
Year 2 -42.76% -24.34%
Year 3 -21.71% -7.83%
Year 4 -3.87% -0.98%
Year 5 11.25% 2.15%
0% -69%Year 1-43%Year 2-22%Year 3-4%Year 411%Year 5

Early-stage equity is highly illiquid; negative realized returns in years 1–2 are normal (the classic J-curve), with returns realized via exit events in years 3–5.

2. Core investment metrics

21.5%
Win rate: probability of a profitable, cash-realized exit
4.19:1
Profit/loss ratio (avg win / avg loss)
1.11×
Expected MOIC (5-yr, realized)
2.1%
5-yr annualized return

3. 5-year capital outcome breakdown (why "cash realized" ≠ "paper alive")

OutcomeProbabilityRealized return to investor
Failure / liquidation26.8%≈ 0 (loss)
Alive but no liquidity event (paper-alive / zombie)40.2%≈ 0 (not realizable)
Cash exit event occurred (profitable exits 21.5%)33.1%Realized per MOIC distribution

Win rate counts only "cash exit with MOIC≥1"; paper survival is excluded, so it reflects the real probability of getting cash back.

4. Sensitivity analysis

Scenario5-yr ROI5-yr ann.Win rate
Pessimistic -40.8% -9.9% 15.3%
Base 11.3% 2.1% 21.5%
Optimistic 78.0% 12.2% 27.5%

5. Upside scenario vs. paper accounting

If exit succeeds

5.06× multiple; ~50.0% annualized (assuming exit in year 4).

Conditional "profitable exit succeeds" scenario for contrast (not an expected value; occurs with only ~21.49% probability).

Paper accounting (not used)

Year-5 survival rate ≈ 68.3%.

Paper basis: counts companies still alive in year 5 at a marked valuation as "value" — a non-cashable paper figure. Official return figures never use this basis.

Go-To-Market

Go-To-Market (GTM)

Google搜索广告自动投放

健康社区内容合作

医生KOL推荐自动邮件

Competition

Competition

WebMD — 无个性化AI解读,更新慢

Mayo Clinic — 仅静态信息,无自动问答

Roadmap

Roadmap

MVP
  • 上线Lipfendra信息AI摘要与问答
扩展
  • 增加个性化健康评估与报告
多药品支持
  • 覆盖更多心血管新药
国际化
  • 拓展非美市场与多语言
Team

Team & Organization

全流程AI自动化,用户自助服务,无需人工介入。

获客 — Google Ads与SEO自动投放(AdWords API),AI生成内容引流

交付 — 用户输入健康数据,GPT-4自动生成个性化报告

客服 — ChatGPT API全天候自动应答常见问题

收款 — Stripe API自动处理订阅与支付

运维 — AWS Lambda+CloudWatch自动监控与弹性扩展

Risks

Risks & Mitigations

RiskMitigation
药品信息更新滞后自动抓取FDA、Merck官网更新
用户健康数据泄露全程加密与合规云服务
AI解读误差药师定期抽查与模型微调
市场需求低于预期扩展到其他新药品类
The Ask

The Ask

Methodology & Sources

Methodology & Sources

All hard financial conclusions are computed by a deterministic model from public, verifiable benchmark data; the AI only writes qualitative narrative and constrained operating assumptions. Out-of-range assumptions are auto-corrected (see above). Returns always use the cash-realized basis.

  1. China startup 1-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
    Over the past decade, ~92% of newly founded Chinese companies survived their first year.
  2. China startup 3-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
    3-year survival ≈76.0% for 2014–2023 cohorts (annual attrition 8.2% / 9.4% / 6.4%).
  3. China startup 5-year survival (interpolated): Interpolated estimate (geometric, between y3 = 0.76 and y10 = 0.503) (2024-05) · Source link
    The report gives no direct 5-year figure; constant-hazard geometric interpolation between years 3 and 10 yields ≈67.5%, explicitly labelled an interpolated estimate.
  4. China startup 10-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
    ≈50.3% of companies survive to year ten.
  5. Average Chinese SME lifespan: People’s Bank of China report (widely cited by Chinese media) (2019-06) · Source link
    Average Chinese SME lifespan ≈3 years (US ≈8 years, Japan ≈12 years).
  6. Share of VC capital realizing <1x: Correlation Ventures — “Venture Capital, We’re Still Not Normal” (2010s decade (realized)) · Source link
    ≈37% of invested capital realized <1x (a loss); by deal count, roughly half of deals lose money.
  7. Share of VC capital realizing ≥10x: Correlation Ventures (2010s decade (realized)) · Source link
    Less than 4% of invested capital realizes ≥10x (the power-law tail).
  8. VC return power law: Correlation Ventures — “The 80/20 Rule for U.S. Venture? Not Exactly.” (2010s decade) · Source link
    Returns are highly right-skewed; a small number of winners contribute most of the profits.
  9. Exit MOIC distribution (calibrated): Calibration: Correlation Ventures realized-return shape + online-asset M&A multiples (Empire Flippers / FE International / Acquire.com, 2026) (2026) · Source link
    MOIC distribution conditional on a realized cash liquidity event (M&A / secondary / buyback); upside is compressed for small online assets (rarely >25x). Bucket probabilities sum to 1.
  10. Annual exit-realization hazard (assumption): Documented assumption: median VC exits take ~5–8 years; small online assets transact faster via Acquire.com / Empire Flippers / FE International; calibrated so the cumulative 5-year exit probability ≈40% conditional on survival. (2026) · Source link
    Cumulative L(t) = 1-(1-h)^t; h = 0.097 → L(5) ≈ 0.40. Explicitly labelled an assumption and stress-tested in the sensitivity analysis.
  11. Micro-SaaS ARR multiple: CT Acquisitions / Empire Flippers / Acquire.com market observations (2026) · Source link
    Micro-SaaS (<$1M ARR) typically trades at 2.5–4x ARR.
  12. Micro-SaaS SDE multiple: FE International / Empire Flippers (2026) · Source link
    Typically 4–6x seller discretionary earnings (SDE); assets with low owner-dependency fetch the high end.
  13. Trend annualization factor (model assumption): Documented model assumption: trending interest decays in pulses; annual topic interest ≈ 30 peak-day equivalents (2026)
    Google Trends volumes are peak-day buckets; annual topic searches ≈ peak-day volume × 30. Explicitly a disclosed model assumption, bounded by the reach limits below.
  14. Capture share (model assumption): Documented model assumption: a focused niche site captures ~1% of annual topic search interest at maturity (2026)
    Derived conservatively from SERP click-share distributions (~28% at #1, ~7% at #5, <1% on page 2); modulated ±50% by data-driven persistence/intent scores.
  15. Reachable-user bounds (model constraint): Documented model constraint: year-3 reachable users are saturation-compressed into [20k, 600k] (2026)
    Lower bound = minimum viable niche audience; upper bound = realistic single-niche-site capacity ceiling. Applied via a saturating function, not a hard clamp.
  16. Zero-human fixed ops base (model assumption): Documented model assumption: hosting/compliance/model-subscription/monitoring base ramps $60k → $90k → $120k over years 1-3 (2026)
    No payroll (zero-human company); includes outsourced legal/finance and exception-handling budget.
  17. Per-active-user marginal cost (model assumption): Documented model assumption: ~$0.8 per active user per year for inference + infrastructure (2026)
    Estimated for lightweight AI workflows with caching and batching.
  18. USD/CNY exchange rate: Recent approximate CNY-per-USD rate (used for conversion; updated as needed) (2026) · Source link
    Exchange rates fluctuate; converted figures are approximations as of the stated date.
  19. Seed-round equity dilution: Industry norm: a single seed round typically dilutes 10%–20% (2026) · Source link
    Baseline 12%; used to convert enterprise-level exit value into the seed investor’s share.
  20. Early-stage venture discount rate: Early-stage VC required rates of return are typically 30%–60% (high risk premium) (2010s) · Source link
    Used for risk-adjusted discounting; baseline 35%.